Inomax
CREST Syndrome
RoseLab Skin Optics LaboratoryDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CREST Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Jose Soberon, MD | Phase 2/3 | B |
Hyaluronidase Brigham and Women's Hospital | Early Phase 1 | C |
Same molecule, other indications
Inomax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →